{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:28:11Z","timestamp":1786685291383,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["DDR\/IIRP23\/4691"],"award-info":[{"award-number":["DDR\/IIRP23\/4691"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09544-3","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:03:02Z","timestamp":1771297382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Protocol of a comparative multicentric non inferiority clinical trial of WHO MBMDT with a new monthly chemotherapy regimen containing rifampicin, moxifloxacin and clarithromycin (RMC) on multibacillary patients from India"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3242-8875","authenticated-orcid":false,"given":"Joydeepa","family":"Darlong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samrun","family":"Nessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utpal","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeta","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartikeyan","family":"Govindasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Maximus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Elkana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamika","family":"Haldar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Miriam","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Jayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"9544_CR1","unstructured":"Treatment | Hansen\u2019s Disease (Leprosy) | CDC n.d. https:\/\/www.cdc.gov\/leprosy\/health-care-workers\/treatment.html. Accessed 10\u00a0Nov 2023."},{"key":"9544_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/0019-5154.108029","volume":"58","author":"M Malathi","year":"2013","unstructured":"Malathi M, Thappa DM. Fixed-duration therapy in leprosy: limitations and opportunities. Indian J Dermatol. 2013;58:93\u2013100. https:\/\/doi.org\/10.4103\/0019-5154.108029.","journal-title":"Indian J Dermatol"},{"key":"9544_CR3","doi-asserted-by":"publisher","unstructured":"Narang T, Almeida JG, Kumar B, Rao PN, Suneetha S, Frade MAC, et al. Fixed duration multidrug therapy (12 months) in leprosy patients with high bacillary load - Need to look beyond. Indian J Dermatol Venereol Leprol 2024;90:64\u20137. https:\/\/doi.org\/10.25259\/IJDVL_278_2023.","DOI":"10.25259\/IJDVL_278_2023"},{"key":"9544_CR4","doi-asserted-by":"publisher","unstructured":"Huang CY, Su SB, Chen KT. An update of the diagnosis, treatment, and prevention of leprosy: A narrative review. Medicine (Baltimore). 2024;103(34):e39006. https:\/\/doi.org\/10.1097\/MD.0000000000039006. PMID: 39183407; PMCID: PMC11346855.","DOI":"10.1097\/MD.0000000000039006"},{"key":"9544_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1128\/CMR.19.2.338-381.2006","volume":"19","author":"DM Scollard","year":"2006","unstructured":"Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19:338\u201381. https:\/\/doi.org\/10.1128\/CMR.19.2.338-381.2006.","journal-title":"Clin Microbiol Rev"},{"key":"9544_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/IJMR.IJMR_12_19","volume":"149","author":"D Scollard","year":"2019","unstructured":"Scollard D. Unfinished business - Leprosy still not defeated. Indian J Med Res. 2019;149:1\u20134. https:\/\/doi.org\/10.4103\/IJMR.IJMR_12_19.","journal-title":"Indian J Med Res"},{"key":"9544_CR7","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/BF02111496","volume":"13","author":"RH Gelber","year":"1994","unstructured":"Gelber RH. Chemotherapy of lepromatous leprosy: recent developments and prospects for the future. Eur J Clin Microbiol Infect Dis. 1994;13:942\u201352. https:\/\/doi.org\/10.1007\/BF02111496.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"9544_CR8","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1128\/AAC.36.11.2544","volume":"36","author":"RH Gelber","year":"1992","unstructured":"Gelber RH, Iranmanesh A, Murray L, Siu P, Tsang M. Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice. Antimicrob Agents Chemother. 1992;36:2544\u20137. https:\/\/doi.org\/10.1128\/AAC.36.11.2544.","journal-title":"Antimicrob Agents Chemother"},{"key":"9544_CR9","first-page":"259","volume":"56","author":"JH Grosset","year":"1988","unstructured":"Grosset JH, Guelpa-Lauras CC, Perani EG, Beoletto C. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int J Lepr Other Mycobact Dis. 1988;56:259\u201364.","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"9544_CR10","first-page":"281","volume":"58","author":"JH Grosset","year":"1990","unstructured":"Grosset JH, Ji BH, Guelpa-Lauras CC, Perani EG, N\u2019Deli LN. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis. 1990;58:281\u201395.","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"9544_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1128\/AAC.38.3.515","volume":"38","author":"GP Chan","year":"1994","unstructured":"Chan GP, Garcia-Ignacio BY, Chavez VE, Livelo JB, Jimenez CL, Parrilla MLR, et al. Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob Agents Chemother. 1994;38:515\u20137. https:\/\/doi.org\/10.1128\/AAC.38.3.515.","journal-title":"Antimicrob Agents Chemother"},{"key":"9544_CR12","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1128\/AAC.40.9.2137","volume":"40","author":"B Ji","year":"1996","unstructured":"Ji B, Jamet P, Perani EG, Sow S, Lienhardt C, Petinon C, et al. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother. 1996;40:2137\u201341. https:\/\/doi.org\/10.1128\/AAC.40.9.2137.","journal-title":"Antimicrob Agents Chemother"},{"key":"9544_CR13","unstructured":"Report of the Global Programme Managers \u2019 Meeting on Leprosy Control Strategy 2009:20\u20132. https:\/\/iris.who.int\/handle\/10665\/206250. Accessed 10\u00a0Nov 2023."},{"key":"9544_CR14","unstructured":"World Health Organization. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. 2018."},{"key":"9544_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000351","author":"SL Walker","year":"2008","unstructured":"Walker SL, Nicholls PG, Butlin CR, Nery JAC, Roy HK, Rangel E, et al. Development and validation of a severity scale for leprosy type 1 reactions. PLoS Negl Trop Dis. 2008. https:\/\/doi.org\/10.1371\/journal.pntd.0000351.","journal-title":"PLoS Negl Trop Dis"},{"key":"9544_CR16","doi-asserted-by":"publisher","unstructured":"Walker SL, Knight KL, Pai V V., Nicholls PG, Alinda M, Butlin CR, et al. The development of a severity scale for Erythema Nodosum Leprosum \u2013 the ENLIST ENL severity scale. Lepr Rev 2016;87:332\u201346. https:\/\/doi.org\/10.47276\/lr.87.3.332.","DOI":"10.47276\/lr.87.3.332"},{"key":"9544_CR17","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1128\/JCM.00512-09","volume":"47","author":"AN Martinez","year":"2009","unstructured":"Martinez AN, Lahiri R, Pittman TL, Scollard D, Truman R, Moraes MO, et al. Molecular determination of Mycobacterium leprae viability by use of real-time PCR. J Clin Microbiol. 2009;47:2124\u201330. https:\/\/doi.org\/10.1128\/JCM.00512-09.","journal-title":"J Clin Microbiol"},{"key":"9544_CR18","doi-asserted-by":"crossref","unstructured":"Lahiri R, Adams LB. Cultivation and viability determination of Mycobacterium leprae. International textbook of leprosy. 2016.","DOI":"10.1489\/itl.5.3"},{"key":"9544_CR19","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1128\/AAC.01162-07","volume":"52","author":"FEF Pardillo","year":"2008","unstructured":"Pardillo FEF, Burgos J, Fajardo TT, Dela Cruz E, Abalos RM, Paredes RMD, et al. Powerful bactericidal activity of moxifloxacin in human leprosy. Antimicrob Agents Chemother. 2008;52:3113\u20137. https:\/\/doi.org\/10.1128\/AAC.01162-07.","journal-title":"Antimicrob Agents Chemother"},{"key":"9544_CR20","doi-asserted-by":"publisher","unstructured":"Francisco Bezerra de Almeida N, Rebeca Daniele Buarque F, Marqueline Soares da S. Daily Moxifloxacin, Clarithromycin, Minocycline, and Clofazimine in Nonresponsiveness Leprosy Cases to Recommended Treatment Regimen. Int J Trop Dis. 2020;3. https:\/\/doi.org\/10.23937\/2643-461X\/1710035.","DOI":"10.23937\/2643-461X\/1710035"},{"key":"9544_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2024.1361641","author":"N Kimta","year":"2024","unstructured":"Kimta N, Majdalawieh AF, Nasrallah GK, Puri S, Nepovimova E, Jomova K, et al. Leprosy: comprehensive insights into pathology, immunology, and cutting-edge treatment strategies, integrating nanoparticles and ethnomedicinal plants. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/FPHAR.2024.1361641.","journal-title":"Front Pharmacol"},{"key":"9544_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/20499361221135885","volume":"9","author":"C Franco-Paredes","year":"2022","unstructured":"Franco-Paredes C, Garcia-Creighton E, Henao-Mart\u00ednez A, Kallgren DL, Banjade R, Dyer JA, et al. Novel approaches in the treatment of Hansen\u2019s disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States. Ther Adv Infect Dis. 2022;9:20499361221135884. https:\/\/doi.org\/10.1177\/20499361221135885.","journal-title":"Ther Adv Infect Dis"},{"key":"9544_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.IJANTIMICAG.2013.03.005","volume":"42","author":"E Rubinstein","year":"2013","unstructured":"Rubinstein E, Keynan Y. Quinolones for mycobacterial infections. Int J Antimicrob Agents. 2013;42:1\u20134. https:\/\/doi.org\/10.1016\/J.IJANTIMICAG.2013.03.005.","journal-title":"Int J Antimicrob Agents"},{"key":"9544_CR24","unstructured":"EasyResearch | SocIT Technologies. n.d. https:\/\/socit-tech.wixsite.com\/home\/easyresearch. Accessed 6\u00a0May 2025."},{"key":"9544_CR25","unstructured":"ICMR policy on health research data management Indian Council of Medical Research. 2023."},{"key":"9544_CR26","doi-asserted-by":"publisher","unstructured":"A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365(9460):711\u201322. ISSN 0140-6736. https:\/\/doi.org\/10.1016\/S0140-6736(05)17965-3.","DOI":"10.1016\/S0140-6736(05)17965-3"},{"key":"9544_CR27","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/j.1365-3156.2011.02873.x","volume":"16","author":"MS Setia","year":"2011","unstructured":"Setia MS, Shinde SS, Jerajani HR, Boivin JF. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis. Trop Med Int Health. 2011;16:1541\u201351. https:\/\/doi.org\/10.1111\/j.1365-3156.2011.02873.x.","journal-title":"Trop Med Int Health"},{"key":"9544_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4269\/ajtmh.2004.70.197","volume":"70","author":"LG Villahermosa","year":"2004","unstructured":"Villahermosa LG, Fajardo TT, Abalos RM, Cellona RV, Balagon MV, Dela Cruz EC, et al. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Am J Trop Med Hyg. 2004;70:197\u2013200.","journal-title":"Am J Trop Med Hyg"},{"key":"9544_CR29","doi-asserted-by":"crossref","unstructured":"Moestopo O, Gunawan H, Dahlan A. Comparison of effectiveness between rifampicin ofloxin-minocycline regimen and multidrug therapy-World Health Organization in multibacillary leprosy patients. Althea Med J. 2016;3(4):661\u20135.","DOI":"10.15850\/amj.v3n4.955"},{"key":"9544_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0012699","volume":"18","author":"P Sivakumaran","year":"2024","unstructured":"Sivakumaran P, Barros B, Antonio Dias VL, Lockwood DN, Walker SL. A retrospective cohort study of monthly rifampicin, ofloxacin and minocycline in the management of leprosy at the Hospital for Tropical Diseases, London, United Kingdom. PLoS Negl Trop Dis. 2024;18:e0012699. https:\/\/doi.org\/10.1371\/journal.pntd.0012699.","journal-title":"PLoS Negl Trop Dis"},{"key":"9544_CR31","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4103\/ijmy.ijmy_58_18","volume":"7","author":"H Gunawan","year":"2018","unstructured":"Gunawan H, Sasmojo M, Putri H, Avriyanti E, Hindritiani R, Suwarsa O. Clinical pilot study: clarithromycin efficacy in multibacillary leprosy therapy. Int J Mycobacteriol. 2018;7:152. https:\/\/doi.org\/10.4103\/ijmy.ijmy_58_18.","journal-title":"Int J Mycobacteriol"},{"key":"9544_CR32","unstructured":"Indian Council of Medical Research. ICMR Guidelines for Good Clinical Laboratory Practices (GCLP) 2021."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09544-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09544-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09544-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:02:20Z","timestamp":1774515740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09544-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9544"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09544-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research will be performed in accordance with the Declaration of Helsinki for Human Research of the World Medical Association. The study protocol was approved by the TLMTI ethics committee (TLMTI\/EC\/C-69), and a written informed consent form will be obtained from the patients before recruitment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"No personally identifying information will be disclosed in any data presentation. All participants will be given the opportunity to review study details and provide informed consent. A sample consent form will be made available upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that there are no known conflicts of interest associated with the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"233"}}